

Reference: 60758390/14592648

Ernst & Young Vietnam Limited
Saigon Riverside Office Center
8th Floor, 2A-4A Ton Duc Thang Street
District 1, Ho Chi Minh City, S.R. of Vietnam

Tel: +84 8 3824 5252 Fax: +84 8 3824 5250 www.ey.com

### INDEPENDENT AUDITORS' REPORT

To: The Shareholders of ICA Biotechnological – Pharmaceuticals Joint Stock Company

We have audited the consolidated balance sheet of ICA Biotechnological - Pharmaceuticals Joint Stock Company and its subsidiaries ("the Group") as at 31 December 2010, the consolidated income statement and consolidated cash flow statement for the year then ended and the notes thereto as set out on pages 4 to 33 (collectively referred to as "the consolidated financial statements"). These consolidated financial statements are the responsibility of the Group's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

#### Basis of opinion

We conducted our audit in accordance with Vietnamese and International Standards on Auditing applicable in Vietnam. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

#### Opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2010, and the consolidated results of its operations and the consolidated cash flows for the year then ended in accordance with the vietnamese Adcounting Standards and System and comply with the relevant statutory requirements.

mist & Young Vietnam Limited

Mai Viet Hung Tran Deputy General Director Registered Auditor

Certificate No. D.0048/KTV

Ho Chi Minh City, Vietnam

28 June 2011

Ronald C. Almera Auditor-in-charge Registered Auditor Certificate No. N.0876/KTV

As member firm of Ernst & Young Global Limited

## ICA Biotechnological – Pharmaceutical Joint Stock Company B01-DN/HN

# CONSOLIDATED BALANCE SHEET as at 31 December 2010

VND

270	то	TAL ASSETS		633,408,155,385	612,416,177,306
269	<i>III.</i>	Goodwill	12	124,514,988,027	137,806,202,331
268		Other long-term assets		454,315,255	411,126,003
261 262		<ol> <li>Long-term prepaid expenses</li> <li>Deferred tax assets</li> </ol>	11 23.2	4,338,443,452 2,139,169,116	4,520,459,050 347.275,407
260	11.	Other long-term assets		6,931,927,823	5,278,860,460
229 230		Accumulated amortisation 3. Construction in progress	10	(77,595,282,363) 12,399,048,024	(48,623,613,537) 12,399,048,024
228		Cost		322,522,435,501	322,522,435,501
223		Accumulated depreciation 2. Intangible fixed assets	9	(51,359,451,937) 244,927,153,138	(45,776,713,972) 273,898,821,964
222 223		Cost		77,917,846,890	77,657,330,344
<b>220</b> 221	<i>I.</i>	Fixed assets  1. Tangible fixed assets	8	<b>283,884,596,115</b> 26,558,394,953	<b>318,178,486,360</b> 31,880,616,372
200		NON-CURRENT ASSETS		415,331,511,965	461,263,549,151
158		Other current assets	7	2,050,129,200	5,364,347,614
		from the State	_	203,142,194	203,142,194
152 154		<ol> <li>Value-added tax deductible</li> <li>Tax and other receivables</li> </ol>		4,170,493,847	5,377,176,615
151		Short-term prepaid expenses	.	742,153,483	289,627,390
150	IV.	Other current assets		7,165,918,724	11,234,293,813
149		<ol><li>Provision for obsolete inventories</li></ol>		(3,493,187,548)	(1,114,579,732)
141		1. Inventories		18,441,650,840	46,059,498,637
140		Inventories	6	14,948,463,292	44,944,918,905
135		Other receivables	5	22,349,077,072 73,687,847,888	22,972,949,082 30,738,115,407
131 132		<ol> <li>Trade receivables</li> <li>Advances to suppliers</li> </ol>		93,035,782,106	34,516,330,890
130	11.	Current accounts receivable		189,072,707,066	88,227,395,379
110	1.	Cash	4	6,889,554,338	6,746,020,058
100	Α.	CURRENT ASSETS		218,076,643,420	151,152,628,155
Code	AS	SETS	Notes	Ending balance	Beginning balance

### ICA Biotechnological – Pharmaceutical Joint Stock Company B01-DN/HN

CONSOLIDATED BALANCE SHEET (continued) as at 31 December 2010

		<del>_</del>		VIVD
Code	RESOURCES	Notes	Ending balance	Beginning balance (As restated – Note 25)
300	A. LIABILITIES		406,524,505,786	402,677,253,530
310	I. Current liabilities		364,141,455,037	344,847,446,317
311	1. Short-term loans	13	165,752,260,092	193,034,260,448
312	Trade payables		74,039,831,011	64,312,444,745
313	Advance to customer	rs	268,611,812	-
314	4. Statutory obligations	14	43,346,539,462	35,932,015,619
315	<ol><li>Payables to employe</li></ol>	es	3,529,093,590	2,221,987,115
316	<ol><li>Accrued expenses</li></ol>	15	20,452,124,418	13,829,478,932
319	<ol><li>Other payables</li></ol>	16	46,250,984,540	23,776,964,859
323	8. Bonus and welfare fu	und	10,502,010,112	11,740,294,599
330	II. Non-current liabilities		42,383,050,749	57,829,807,213
331	<ol> <li>Long-term trade paya</li> </ol>		7,572,800,000	8,970,500,000
333	<ol><li>Other long-term liabil</li></ol>		250,000,500	230,000,000
334	<ol><li>Long-term loans</li></ol>	17	31,105,000,000	46,093,717,389
336	<ol> <li>Provision for severar allowance</li> </ol>	nce	3,455,250,249	2,535,589,824
400	B. OWNERS' EQUITY	18.1	226,862,046,714	209,722,424,444
410	I. Capital		226,862,046,714	209,722,424,444
411	Share capital	18.2	116,500,000,000	116,500,000,000
412	<ol> <li>Share premium</li> </ol>		13,475,000,000	13,475,000,000
417	<ol><li>Investment and deve</li></ol>	elopment		
	fund		22,421,624,675	17,550,526,900
418	<ol><li>Financial reserve fun</li></ol>		9,047,429,987	6,611,881,100
419	<ol><li>Other funds belonging</li></ol>	g to		
	owners' equity		4,326,764,700	4,326,764,700
420	6. Undistributed earning	gs	61,091,227,352	51,258,251,744
439	C. MINORITY OF INTERES	STS	21,602,885	16,499,332
440	TOTAL LIABILITIES AND OWNERS' EQUITY		6 <u>33,4</u> 08,155,385	612,416,177,306
			000,400,100,000	

Nguyen Huy Khang Chief Accountant

28 June 2011

CÔNG TY CỔ PHẨN CÔNG NGHỆ SINH ĐỘC

> AN-THUMAG Quang Son General Director

## ICA Biotechnological – Pharmaceutical Joint Stock Company B02-DN/HN

CONSOLIDATED INCOME STATEMENT for the year ended 31 December 2010

١	1	1	١	11	
- 1	v	1	v	L	_

				VIVL
Code	ITEMS	Notes	Current year	Previous year (As restated – Note 25)
01	Revenue from sale of goods	19.1	346,175,732,505	318,566,931,823
02	2. Deductions	19.1	(188,894,420)	(3,545,736,141)
10	3. Net revenue from sale of goods	19.1	345,986,838,085	315,021,195,682
11	4. Cost of goods sold	20, 22	(163,493,589,179)	(197,072,265,702)
20	5. Gross profit		182,493,248,906	117,948,929,980
21	6. Finance income	19.2	1,768,014,142	16,829,417,583
<b>22</b> 23	7. Finance expenses In which: Interest expense	21	(23,840,392,589) (20,815,841,548)	(32,746,639,520) (19,235,288,533)
24	8. Selling expenses	22	(50,120,723,090)	(32,367,455,756)
25	9. General and administration expenses	22	(58,330,611,009)	(21,090,104,697)
30	10. Operating profit		51,969,536,360	48,574,147,590
31	11. Other income		1,195,755,645	260,430,868
32	12. Other expenses		(120,940,685)	(73,302,477)
40	13. Other profit		1,074,814,960	187,128,391
50	14. Profit before tax		53,044,351,320	48,761,275,981
51	15. Current corporate income tax expense	23.1	(4,669,640,988)	(3,572,711,583)
52	16. Deferred corporate income tax benefit (expense)	23.2	1,791,893,709	(221,639,209)
60	17. Net profit after tax In which:		50,166,604,041	44,966,925,189
61	17.1. Minority interest		5,103,553 50,161,500,488	- 44,966,925,189
62 <b>80</b>	<ul><li>17.2. Equity holders of the parent</li><li>18. Basic earnings per share</li></ul>	14	30,161,300,488 A6030003204,306	3,860

Mguyen Huy Khang Chief Accountant

28 June 2011

CÔNG NGHỆ SINH HẠC DƯỢC PHẨM

ICA
Lugning Quang Son
AN-T. General Director

## ICA Biotechnological – Pharmaceutical Joint Stock Company B03-DN/HN

CONSOLIDATED CASH FLOW STATEMENT for the year ended 31 December 2010

				VIVL
Code	ITEMS	Notes	Current year	Previous year (As restated – Note 25)
	I. CASH FLOWS FROM			
	OPERATING ACTIVITIES			
01	Profit before tax		53,044,351,320	48,761,275,981
	Adjustments for:			
02	Depreciation and amortisation	8, 9, 12	48,290,343,694	21,178,501,119
03 04	Provisions		2,378,607,816	(698,088,827)
04	Unrealised foreign exchange losses		440,987,234	0 000 200 250
05	Gain from investing activities		(182,079,780)	8,892,380,352 (14,146,265,809)
06	Interest expense	21	20,815,841,548	19,235,288,533
	· ·		,,,	,,,
08	Operating profit before changes			
	in working capital		124,788,051,832	83,223,091,349
09 10	Increase in receivables		(96,725,225,463)	(3,466,754,992)
10	Decrease (increase) in inventories		27,617,847,797	(4,125,047,336)
11	Increase (decrease) in		27,017,047,737	(4,120,047,330)
	payables		6,974,384,471	(2,438,589,450)
12	Increase in prepaid expenses		(270,510,495)	(224,469,813)
13	Interest paid		(15,464,796,547)	(16,016,746,348)
14	Corporate income tax paid	23.1	~	(478,735,556)
16	Other cash outflows from		(F 40F 400 70F)	(4.000.470.004)
	operating activities	1	(5,135,162,705)	(1,306,179,021)
20	Net cash flows from operating			
	activities		41,784,588,890	55,166,568,833
	II. CASH FLOWS FROM INVESTING ACTIVITIES			
21	Purchase of fixed assets		(705,239,145)	(1,348,615,940)
26	Payment for acquisition of		(100,200,110)	(1,010,010,010)
	subsidiaries, net of cash			
	acquired		-	(15,785,519,482)
28	Interest received		182,079,780	185,385,788
30	Net cash flows used in investing			
30	activities		(523,159,365)	(16,948,749,634)
			(320, 130,000)	(,5,. 10,00-1)
	III. CASH FLOWS FROM			
	FINANCING ACTIVITIES			
33	Drawdown of borrowings		74,572,667,406	157,670,762,711
34	Repayment of borrowings		(115,690,562,651)	(162,862,022,200)
36	Dividends paid		-	(30,608,250,000)
40	Net cash flows used in financing			
	activities		(41,117,895,245)	(35,799,509,489)

### ICA Biotechnological – Pharmaceutical Joint Stock Company B03-DN/HN

CONSOLIDATED CASH FLOW STATEMENT (continued) for the year ended 31 December 2010

VND

Code	ITEMS	Notes	Current year	Previous year (As restated – Note 25)
50	Net increase in cash		143,534,280	2,418,309,710
60	Cash at beginning of year	4	6,746,020,058	4,327,710,348
70	Cash at end of year	4	6,889,554,338	6,746,020,058

CÔNG TY CỔ PHẨN CÔNG NGHỆ SINH HỘC DƯỢC PHẨM

NAN-T. General Director

Nguyen Huy Khang Chief Accountant

28 June 2011